etopos
eurofarma laboratÓrios s.a. - etoposido - antineoplasico
tarvexol
sandoz do brasil indÚstria farmacÊutica ltda - paclitaxel - antineoplasico
evotaxel
evolabis produtos farmacÊuticos ltda - antineoplasico
evotaxel
hospira produtos hospitalares ltda - antineoplasico
evotaxel
wyeth indÚstria farmacÊutica ltda - antineoplasico
tevapacli
teva farmacÊutica ltda. - antineoplasico
imfinzi
astrazeneca ab - durvalumab - carcinoma, pulmão de células não pequenas - agentes antineoplásicos - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).
brecila
accord farmacÊutica ltda - cloridrato de epirrubicina - antibioticos antineoplasicos
c-platin
blau farmacÊutica s.a. - cisplatina - antineoplasico
cisplatina
accord farmacÊutica ltda - cisplatina - antineoplasico